Targeting IL-23 and Th17-Cytokines in Inflammatory Bowel Diseases

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|16|33|3656-3660

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.16, Iss.33, 2010-11, pp. : 3656-3660

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 11, Iss. 2, 2012-04 ,pp. : 159-168

Bentham Science Publishers

Access to resources Recommend Favorite

Lactic Acid Bacteria with Concomitant IL-17, IL-23 and TNFα- Binding Ability for the Treatment of Inflammatory Bowel Disease

By  

Current Pharmaceutical Biotechnology, Vol. 18, Iss. 4, 2017-05 ,pp. : 318-326

Bentham Science Publishers

Access to resources Recommend Favorite

Th22 and related cytokines in inflammatory and autoimmune diseases

By Tian Tian   Yu Shuang   Ma Daoxin  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 2, 2013-02 ,pp. : 113-125

Informa Healthcare

Access to resources Recommend Favorite

Aberrant frequency of IL-10-producing B cells and its association with the balance of Treg/Th17 in children with inflammatory bowel disease

By Zhu Xiao-Min   Huang Yi-Min   Fan Jian-Feng   Shi Ying-Zuo  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 10, 2015-10 ,pp. : 656-660

Govi-Verlag

Access to resources Recommend Favorite

Targeting IL-17 and IL-23 in Immune Mediated Renal Disease

By  

Current Medicinal Chemistry, Vol. 22, Iss. 38, 2015-12 ,pp. : 4341-4365

Bentham Science Publishers

Access to resources Recommend Favorite